Beta-2 adrenergic receptor
The beta-2 adrenergic receptor, also known as ADRB2, is a cell membrane-spanning beta-adrenergic receptor that binds epinephrine, a hormone and neurotransmitter whose signaling, via adenylate cyclase stimulation through trimeric Gs proteins, increased cAMP, and downstream L-type calcium channel interaction, mediates physiologic responses such as smooth muscle relaxation and bronchodilation.
The official symbol for the human gene encoding the β2 adrenoreceptor is ADRB2.
Gene
The gene is intronless. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity and type 2 diabetes.Structure
The 3D crystallographic structure of the β2-adrenergic receptor has been determined by making a fusion protein with lysozyme to increase the hydrophilic surface area of the protein for crystal contacts. An alternative method, involving production of a fusion protein with an agonist, supported lipid-bilayer co-crystallization and generation of a 3.5 Å resolution structure.Mechanism
This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel CaV1.2. This receptor-channel complex is coupled to the Gs G protein, which activates adenylyl cyclase, catalysing the formation of cyclic adenosine monophosphate which then activates protein kinase A, and counterbalancing phosphatase PP2A. Protein kinase A then goes on to phosphorylate myosin light-chain kinase, which causes smooth muscle relaxation, accounting for the vasodilatory effects of beta 2 stimulation. The assembly of the signaling complex provides a mechanism that ensures specific and rapid signaling. A two-state biophysical and molecular model has been proposed to account for the pH and REDOX sensitivity of this and other GPCRs.Beta-2 adrenergic receptors have also been found to couple with Gi, possibly providing a mechanism by which response to ligand is highly localized within cells. In contrast, Beta-1 adrenergic receptors are coupled only to Gs, and stimulation of these results in a more diffuse cellular response. This appears to be mediated by cAMP induced PKA phosphorylation of the receptor.
Function
Muscular system
The β2 adrenoreceptor has been correlated with anabolic properties and muscular hypertrophy with usage of agents such as oral clenbuterol as well as intravenous albuterol, though oral albuterol did not generate the same impacts on muscle mass, suggesting that drugs with a short half-life do not maintain sufficient activation to achieve these effects. Long-acting β2 agonists such as clenbuterol are frequently abused performance-enhancing drugs for their anabolic, lipolytic, and performance-enhancing effects. As a result, most of these agents are banned by WADA, though some are permissible under a therapeutic use exemption and are typically monitored for usage in athletes. Clenbuterol remains banned not as a beta-agonist, but rather an anabolic agent.Function | Tissue | Biological Role |
Smooth muscle relaxation in: | GI tract | Inhibition of digestion |
Smooth muscle relaxation in: | Bronchi | Facilitation of respiration. Hence, beta-2 agonists can be useful in treating asthma. |
Smooth muscle relaxation in: | Detrusor urinae muscle of bladder wall This effect is stronger than the alpha-1 receptor effect of contraction. | Inhibition of need for micturition |
Smooth muscle relaxation in: | Uterus | Inhibition of labor |
Smooth muscle relaxation in: | Seminal tract | |
Increased perfusion and vasodilation | Blood vessels and arteries to skeletal muscle including the smaller coronary arteries and hepatic artery | Facilitation of muscle contraction and motility |
Increased mass and contraction speed | Striated muscle | Facilitation of muscle contraction and motility |
Insulin and glucagon secretion | Pancreas | Increased blood glucose and uptake by skeletal muscle |
Glycogenolysis | Increased blood glucose and uptake by skeletal muscle | |
Tremor | Motor nerve terminals. Tremor is mediated by PKA mediated facilitation of presynaptic Ca2+ influx leading to acetylcholine release. |
Circulatory system
- Heart muscle contraction
- Increase cardiac output.
- *Increases heart rate in sinoatrial node .
- *Increases atrial cardiac muscle contractility..
- *Increases contractility and automaticity of ventricular cardiac muscle.
- Dilate hepatic artery.
- Dilate arterioles to skeletal muscle.
Eye
- Increase in production of aqueous humour by the ciliary process,
- Subsequent increased pressure-dependent uveoscleral outflow of humour, despite reduced drainage of humour via the Canal of Schlemm.
Digestive system
- Glycogenolysis and gluconeogenesis in liver.
- Glycogenolysis and lactate release in skeletal muscle.
- Contract sphincters of Gastrointestinal tract.
- Thickened secretions from salivary glands.
- Insulin and glucagon secretion from pancreas.
Other
- Inhibit histamine-release from mast cells.
- Increase protein content of secretions from lacrimal glands.
- Receptor also present in cerebellum.
- Bronchiole dilation
- Involved in brain - immune - communication
Ligands
Agonists
Spasmolytics used in [asthma] and COPD">Chronic obstructive pulmonary disease">COPD
- Short-acting β2 agonists
- * bitolterol
- * fenoterol
- * hexoprenaline
- * isoprenaline or isoproterenol
- * levosalbutamol or levalbuterol
- * orciprenaline or metaproterenol
- * pirbuterol
- * procaterol
- * salbutamol or albuterol
- * terbutaline
- Long-acting β2 agonists
- * arformoterol
- * bambuterol
- * clenbuterol
- * formoterol
- * salmeterol
- Ultra-long-acting β2 agonists
- * carmoterol
- * indacaterol
- * milveterol
- * olodaterol
- * vilanterol
[Tocolytic] agents
- Short-acting β2 agonists
- * fenoterol
- * hexoprenaline
- * isoxsuprine
- * ritodrine
- * salbutamol or albuterol
- * terbutaline
β2 agonists used for other purposes
- zilpaterol
Antagonists
- butoxamine*
- First generation β-blockers
- ICI-118,551*
- Propranolol
Allosteric modulators
- compound-6FA, PAM at intracellular binding site
Interactions